Treatment outcome of tuberculosis patient of Samtse General Hospital, Bhutan.
Asia
Mycobacterium Infections
Patient Outcome Assessment
Successful
Therapy
Journal
Nepal journal of epidemiology
ISSN: 2091-0800
Titre abrégé: Nepal J Epidemiol
Pays: Nepal
ID NLM: 101583212
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
09
04
2020
revised:
04
09
2020
accepted:
07
09
2020
entrez:
12
10
2020
pubmed:
13
10
2020
medline:
13
10
2020
Statut:
epublish
Résumé
Tuberculosis (TB) is one of the major public health problems in Bhutan. Evaluation of treatment outcomes of TB and identification of the risk factors are important components for the success of National TB control program. Therefore, this study was undertaken to assess the TB treatment outcome and factors associated with it in Samtse General Hospital. This was a retrospective, cross sectional study using the TB data from Samtse General Hospital from 2008-2019. A univariate and multiple logistic regression was used to check for associations between the outcome and other independent variables. The study included a total of 634 TB patients. Of this, 44.0% (279) were smear positive TB (PTB+), 36.1% (229) were extra pulmonary TB (EPTB) and 19.9% (126) were smear negative TB (PTB-). During the study period, 56.2% (356) of them completed treatment, 33.3% (211) were declared cured, 0.2% (1) had defaulted, 5.1% (32) died and 5.4% (34) had treatment failure. The mean treatment success rate (TSR) was 89.4% (567). The TSR was highest for EPTB with 96.9% (222/229), followed by PTB- at 88.1% (111/126) and lowest for PTB+ with 83.9% (234/279). Successful treatment outcome was observed in EPTB patients (AOR: 7.3; 95% CI: 2.46-21.36), patients in age 15-28 years (AOR: 3.4; 95% CI: 1.59-7.46) and 29-42 years (AOR: 9.1; 95% CI: 2.44-33.61). The treatment outcome of TB in Samtse General Hospital is satisfactory and at par with the national level. Since, smear positive TB and elderly patients are prone to develop poor treatment outcome, they need to be monitored and followed up adequately.
Sections du résumé
BACKGROUND
BACKGROUND
Tuberculosis (TB) is one of the major public health problems in Bhutan. Evaluation of treatment outcomes of TB and identification of the risk factors are important components for the success of National TB control program. Therefore, this study was undertaken to assess the TB treatment outcome and factors associated with it in Samtse General Hospital.
METHODS
METHODS
This was a retrospective, cross sectional study using the TB data from Samtse General Hospital from 2008-2019. A univariate and multiple logistic regression was used to check for associations between the outcome and other independent variables.
RESULTS
RESULTS
The study included a total of 634 TB patients. Of this, 44.0% (279) were smear positive TB (PTB+), 36.1% (229) were extra pulmonary TB (EPTB) and 19.9% (126) were smear negative TB (PTB-). During the study period, 56.2% (356) of them completed treatment, 33.3% (211) were declared cured, 0.2% (1) had defaulted, 5.1% (32) died and 5.4% (34) had treatment failure. The mean treatment success rate (TSR) was 89.4% (567). The TSR was highest for EPTB with 96.9% (222/229), followed by PTB- at 88.1% (111/126) and lowest for PTB+ with 83.9% (234/279). Successful treatment outcome was observed in EPTB patients (AOR: 7.3; 95% CI: 2.46-21.36), patients in age 15-28 years (AOR: 3.4; 95% CI: 1.59-7.46) and 29-42 years (AOR: 9.1; 95% CI: 2.44-33.61).
CONCLUSION
CONCLUSIONS
The treatment outcome of TB in Samtse General Hospital is satisfactory and at par with the national level. Since, smear positive TB and elderly patients are prone to develop poor treatment outcome, they need to be monitored and followed up adequately.
Identifiants
pubmed: 33042592
doi: 10.3126/nje.v10i3.28397
pmc: PMC7538015
doi:
Types de publication
Journal Article
Langues
eng
Pagination
888-896Informations de copyright
© 2020 CEA& INEA.
Déclaration de conflit d'intérêts
Competing interests There is no conflict of interest for any author of this manuscript.
Références
Public Health Action. 2017 Jun 21;7(2):134-140
pubmed: 28695087
BMC Infect Dis. 2008 Jan 24;8:8
pubmed: 18218115
Int J Tuberc Lung Dis. 2013 Apr;17(4):468-72
pubmed: 23485380
BMC Public Health. 2011 Dec 13;11:921
pubmed: 22166132
Sci Rep. 2019 Sep 10;9(1):12995
pubmed: 31506499
Int J Tuberc Lung Dis. 2004 Apr;8(4):458-64
pubmed: 15141739
Int J Tuberc Lung Dis. 2005 Nov;9(11):1224-9
pubmed: 16333929
Tuberc Res Treat. 2019 Apr 1;2019:1503219
pubmed: 31057963
PLoS One. 2018 Oct 18;13(10):e0205468
pubmed: 30335777
PLoS One. 2016 Feb 26;11(2):e0150560
pubmed: 26918458
BMC Res Notes. 2012 Jun 20;5:311
pubmed: 22715941
Thorax. 2008 May;63(5):440-6
pubmed: 17615085
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28242663
J Clin Tuberc Other Mycobact Dis. 2018 Jul 03;12:41-47
pubmed: 31720398
BMC Infect Dis. 2018 Mar 5;18(1):104
pubmed: 29506480
Pan Afr Med J. 2018 Aug 28;30:293
pubmed: 30637077
Public Health Action. 2013 Mar 21;3(1):38-42
pubmed: 26392994